AU766001B2 - Rivastigmine for the treatment of ocular disorders - Google Patents

Rivastigmine for the treatment of ocular disorders Download PDF

Info

Publication number
AU766001B2
AU766001B2 AU28349/01A AU2834901A AU766001B2 AU 766001 B2 AU766001 B2 AU 766001B2 AU 28349/01 A AU28349/01 A AU 28349/01A AU 2834901 A AU2834901 A AU 2834901A AU 766001 B2 AU766001 B2 AU 766001B2
Authority
AU
Australia
Prior art keywords
ethyl
compound
glaucoma
methyl
lower alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU28349/01A
Other languages
English (en)
Other versions
AU2834901A (en
Inventor
David Goldblum
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2834901A publication Critical patent/AU2834901A/en
Application granted granted Critical
Publication of AU766001B2 publication Critical patent/AU766001B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU28349/01A 1999-10-19 2000-10-17 Rivastigmine for the treatment of ocular disorders Ceased AU766001B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP99120678 1999-10-19
EP99120678 1999-10-19
PCT/EP2000/010234 WO2001028553A1 (en) 1999-10-19 2000-10-17 Rivastigmine for the treatment of ocular disorders

Publications (2)

Publication Number Publication Date
AU2834901A AU2834901A (en) 2001-04-30
AU766001B2 true AU766001B2 (en) 2003-10-09

Family

ID=8239225

Family Applications (1)

Application Number Title Priority Date Filing Date
AU28349/01A Ceased AU766001B2 (en) 1999-10-19 2000-10-17 Rivastigmine for the treatment of ocular disorders

Country Status (13)

Country Link
US (2) US6534541B1 (enExample)
EP (1) EP1225890B1 (enExample)
JP (1) JP2003512324A (enExample)
AR (1) AR026062A1 (enExample)
AT (1) ATE285764T1 (enExample)
AU (1) AU766001B2 (enExample)
CA (1) CA2384690C (enExample)
DE (1) DE60017174T2 (enExample)
DK (1) DK1225890T3 (enExample)
ES (1) ES2234708T3 (enExample)
NZ (1) NZ518164A (enExample)
PT (1) PT1225890E (enExample)
WO (1) WO2001028553A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2237163T3 (es) 1998-10-01 2005-07-16 Novartis Ag Nuevas formulaciones orales de revastigmina de liberacion controlada.
US9993558B2 (en) 2004-10-01 2018-06-12 Ramscor, Inc. Sustained release eye drop formulations
US8541413B2 (en) * 2004-10-01 2013-09-24 Ramscor, Inc. Sustained release eye drop formulations
WO2009022345A1 (en) * 2007-08-14 2009-02-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem Phenyl carbamates for the treatment of multiple sclerosis
US12478503B2 (en) 2009-05-18 2025-11-25 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
WO2011151359A1 (en) 2010-06-02 2011-12-08 Noscira, S.A. Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative
CN107417574B (zh) * 2017-03-21 2019-12-03 浙江省医学科学院 2,4-双取代苯乙酮化合物及其旋光异构体、药学上可接受的盐及应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL74497A (en) 1985-03-05 1990-02-09 Proterra Ag Pharmaceutical compositions containing phenyl carbamate derivatives and certain phenyl carbamate derivatives
HU201906B (en) * 1987-03-04 1991-01-28 Sandoz Ag Process for producing phenyl-carbamate derivative and acid additional salts and pharmaceutical compositions containing them
US4900748A (en) 1988-03-04 1990-02-13 The United States Of America As Represented By The Department Of Health And Human Services Carbamates related to (-)-physostigmine as cholinergic agents
JP3708957B2 (ja) 1991-09-26 2005-10-19 アメリカ合衆国 （−）−エゼロリン、（−）−ｎ１−ノルエゼロリンおよび（−）−ｎ１−ベンジルノルエゼロリンの置換フェンゼリンおよびフェニルカルバミン酸塩：特異的アセチルコリンエステラーゼ阻害薬としての使用
ES2206449T3 (es) 1991-09-26 2004-05-16 The Government Of The Usa As Represented By The Secretary Of Department Of Health And Human Services Inhibidores de colinesterasas, composiciones farmaceuticas y sus usos.
AU1138097A (en) * 1995-12-22 1997-07-17 Alcon Laboratories, Inc. Combinations of prostaglandins and miotics for lowering intraocular pressure

Also Published As

Publication number Publication date
ES2234708T3 (es) 2005-07-01
US6835748B2 (en) 2004-12-28
PT1225890E (pt) 2005-05-31
JP2003512324A (ja) 2003-04-02
AR026062A1 (es) 2002-12-26
NZ518164A (en) 2003-10-31
EP1225890B1 (en) 2004-12-29
DK1225890T3 (da) 2005-04-04
WO2001028553A1 (en) 2001-04-26
DE60017174T2 (de) 2005-12-22
US20030119832A1 (en) 2003-06-26
US6534541B1 (en) 2003-03-18
AU2834901A (en) 2001-04-30
CA2384690C (en) 2010-08-17
DE60017174D1 (de) 2005-02-03
ATE285764T1 (de) 2005-01-15
EP1225890A1 (en) 2002-07-31
CA2384690A1 (en) 2001-04-26

Similar Documents

Publication Publication Date Title
CA1208560A (en) Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma
US5863948A (en) Increasing aqueous humor outflow
JPH10507743A (ja) 薬剤投与のための方法と手段
WO1989010757A1 (en) New ophthalmic preparation for treating glaucoma
US9694010B2 (en) Therapeutic formulation and methods of treatment
AU766001B2 (en) Rivastigmine for the treatment of ocular disorders
DE60132494T2 (de) Kupferchelatbildner zur behandlung von augenentzündungen
US5527831A (en) Pharmaceutical composition for topical application to the eye for treating increased intraocular pressure
KR20010040457A (ko) 안약 조성물
US5196449A (en) Methods and pharmaceutical compositions for the treatment of ophthalmic diseases
RU2434633C2 (ru) Фармацевтические препаративные формы латрункулина
Goldblum et al. Topical rivastigmine, a selective acetylcholinesterase inhibitor, lowers intraocular pressure in rabbits
KR19980063712A (ko) 망막증의 치료에 유용한 저급 알카노일 ｌ-카르니틴
TW304879B (enExample)
US4477460A (en) Topical treatment of ocular hypertension
RU2118523C1 (ru) Офтальмологическое средство преимущественно для лечения глаукомы
WO1995008990A1 (en) Increasing aqueous humor outflow

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)